

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



New Ray Medicine  
新銳醫藥

## **New Ray Medicine International Holding Limited**

**新銳醫藥國際控股有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock Code: 6108)**

### **INSIDE INFORMATION – SUBSTANTIAL REDUCTION IN LOSS**

This announcement is made by New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) (“**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (“**Directors**”) of the Company (“**Board**”) wishes to inform the shareholders of the Company (“**Shareholders**”) and potential investors that, based on a preliminary review and analysis of the latest available unaudited consolidated management accounts of the Company, it is expected that the Group will record a net loss of not more than HK\$5.0 million for the six months ended 30 June 2024 (“**1H 2024**”) as compared to the net loss of approximately HK\$13.4 million recorded by the Group for the six months ended 30 June 2023 (“**1H 2023**”).

The expected substantial reduction in loss for 1H 2024 was primarily due to (i) the recognition of the net exchange losses of approximately HK\$1.2 million for 1H 2024 as compared to the net exchange losses of approximately HK\$7.0 million for 1H 2023; (ii) the recognition of the impairment loss on trade and other receivables of approximately HK\$0.1 million for 1H 2024 as compared to the impairment loss on trade and other receivables of approximately HK\$2.2 million for 1H 2023; and (iii) the decrease in the marketing service fee and delivery expenses in line with the decrease in sales volume of the Group’s major product under the second generation of Cephalosporins (二代頭孢產品) (1.0g).

The Company is still in the process of preparing and finalising its unaudited condensed consolidated financial statements for 1H 2024. The information contained in this announcement is only based on a preliminary assessment made by the Board with reference to the information currently available, which has not been reviewed or audited by the auditors of the Company and may be subject to change or adjustments. Shareholders and potential investors are advised to refer to the details of the Group's unaudited financial results for 1H 2024, which are expected to be published on 28 August 2024.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

On behalf of the Board  
**New Ray Medicine International Holding Limited**  
**Wang Qiuqin**  
*Chairman & Executive Director*

Hong Kong, 21 August 2024

*As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong, Mr. Chu Xueping and Ms. Zhou Wan; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.*